Nymox Pharmaceutical Corporation (NYMX)

NASDAQ: NYMX · IEX Real-Time Price · USD
1.26
0.01 (0.80%)
At close: May 20, 2022 4:00 PM
1.22
-0.04 (-3.17%)
After-hours:May 20, 2022 7:16 PM EDT
Market Cap113.75M
Revenue (ttm)n/a
Net Income (ttm)-15.18M
Shares Out90.28M
EPS (ttm)-0.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume40,925
Open1.25
Previous Close1.25
Day's Range1.22 - 1.27
52-Week Range0.94 - 2.27
Beta1.09
Analystsn/a
Price Targetn/a
Earnings DateMay 13, 2022

About NYMX

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAler...

IndustryBiotechnology
IPO DateDec 1, 1997
Employees3
Stock ExchangeNASDAQ
Ticker SymbolNYMX
Full Company Profile

Financial Performance

Financial Statements

News

Nymox Announces Closing of $6.4 Million Financing

IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has closed its $6.4 million financing announced in its f...

1 month ago - GlobeNewsWire

Nymox Announces $5 Million Registered Direct Offering

IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors f...

2 months ago - GlobeNewsWire

NYMOX Announces Submission of New Drug Application (NDA) to the FDA for Fexapotide Triflutate

IRVINE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that it has submitted the Company's New Drug Application (...

2 months ago - GlobeNewsWire

Nymox Shareholder Update

HASBROUCK HEIGHTS, N.J., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has completed all the Company's required tasks i...

5 months ago - GlobeNewsWire

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

NYMOX Provides Current Update NYMOX Provides Current Update

6 months ago - GlobeNewsWire

NYMOX Provides Current Update

HASBROUCK HEIGHTS, N.J., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to report today a one-month update to shareholders as a follow-up to...

7 months ago - GlobeNewsWire

NYMOX Provides Shareholder Update

HASBROUCK HEIGHTS, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide an update on the Company's progress with its BPH treatme...

8 months ago - GlobeNewsWire

4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%

These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other symbols:HEPALPTXVSTM
8 months ago - PennyStocks

Nymox Announces Date for Fexapotide Filing

HASBROUCK HEIGHTS, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it will be filing for marketing approval of Fexapoti...

1 year ago - GlobeNewsWire

Nymox Announces $8,000,000 Private Placement

HASBROUCK HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with institutional ...

1 year ago - GlobeNewsWire

Nymox Provides New Update on Regulatory Activities

HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activit...

1 year ago - GlobeNewsWire

Nymox Provides Update on Regulatory Filing Activities

HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutat...

1 year ago - GlobeNewsWire

Nymox Announces $9 Million Registered Direct Offering

HASBROUCK HEIGHTS, N.J., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited i...

1 year ago - GlobeNewsWire

NYMOX Provides Current Update on Key Company Developments

HASBROUCK HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report current updates on the Company's most important ongoing developments. Th...

1 year ago - GlobeNewsWire

Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement

HASBROUCK HEIGHTS, N.J., June 19, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations have been ...

1 year ago - GlobeNewsWire

Nymox Announces Important New Patent Developments

HASBROUCK HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international patents...

2 years ago - GlobeNewsWire

Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of ...

HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a new peer review report was published today in the World Journal...

2 years ago - GlobeNewsWire

Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

HASBROUCK HEIGHTS, N.J., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of...

2 years ago - GlobeNewsWire

Nymox Provides Update on Current Corporate Activities and Milestones

HASBROUCK HEIGHTS, N.J., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current January 2020 update on several important corporate activities...

2 years ago - GlobeNewsWire

Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research an...

HASBROUCK HEIGHTS, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on experimental stu...

2 years ago - GlobeNewsWire

Nymox Reports on Newly Issued Patents and Corporate Developments

HASBROUCK HEIGHTS, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report very positive fundamental news, that the Company has received several ne...

2 years ago - GlobeNewsWire

6 Stocks to Buy Based on Insider Buying

Insiders only buy their stocks for one reason -- to make money. Here are 6 stocks to buy based on the recent insider buying.

Other symbols:CCLGEFHOFTKRPLAY
2 years ago - InvestorPlace